Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

60.16
+0.16000.27%
Post-market: 60.160.00000.00%19:33 EDT
Volume:637.20K
Turnover:38.44M
Market Cap:5.81B
PE:-12.78
High:61.75
Open:60.56
Low:59.68
Close:60.00
52wk High:72.66
52wk Low:35.60
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.87
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:4.68
PE(LYR):-13.78

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

Xenon Pharmaceuticals Exec Says All Four Labeled Doses -10, 15, 20 and 25 Mg - Will Have Flat Pricing, Allowing Physicians to Start and Escalate Doses - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Azetukalner’s Data and Novel Mechanism “Demands” Optimized Pricing, Adding a Prior Therapy Was “Underpriced” - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Co Expects to Be “Extremely Well Positioned” for Launch of Azetukalner - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Shares Jump 16.5% Premarket After Co's Epilepsy Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Mar 09

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Reuters
·
Mar 09

Top Premarket Gainers

MT Newswires Live
·
Mar 09

Xenon Pharmaceuticals Inc - Azetukalner Demonstrates Consistent Safety Profile in X-Tole2 Study

THOMSON REUTERS
·
Mar 09

Xenon Announces Positive Topline Data From Phase 3 X-Tole2 Study of Azetukalner in Focal Onset Seizures (Fos)

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Inc: Anticipates Submitting New Drug Application for Azetukalner in Fos to U.S. FDA in Q3 2026

THOMSON REUTERS
·
Mar 09

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:58 AM

Reuters
·
Mar 09

Xenon Pharmaceuticals to report Phase 3 X-TOLE2 azetukalner focal seizure trial topline results March 9, 2026

Reuters
·
Mar 09

Xenon to Announce Topline Results From Phase 3 X-Tole2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

THOMSON REUTERS
·
Mar 09